

Table S1 Original data for Figure 1

Patient No		1	2	3	4	5	6	7	8	9	10	11	12
Before tofacitinib treatment	ESR (mm/h)	16	16	28	14	6	21	46	13	29	29	26	14
	hs-CRP (mg/L)	6.29	6.27	24.75	4.50	1.49	5.19	5.33	7.50	15.39	11.83	13.7	5.8
	VAS	7	4	10	6	6	4	7	5	8	5	6	4
	HAQ-DI	0.70	0.15	0	0.65	0.60	0.05	0	0.60	1.80	0.90	0.30	0.25
	BASDAI	5.2	3.0	-	-	-	-	-	3.5	7.4	-	-	1.8
	BASFI	4.8	1.1	-	-	-	-	-	1.2	2.8	-	-	1.2
After tofacitinib treatment	ESR (mm/h)	10	13	13	11	2	7	33	7	9	16	10	4
	hs-CRP (mg/L)	2.66	3.61	4.05	0.71	0.91	0.28	4.50	3.16	0.74	1.12	4.27	0.24
	VAS	1	2	3	3	2	0	8	2	5	1	0	1
	HAQ-DI	0.65	0.15	0	0.55	0.30	0.05	0.05	0.60	0.45	0	0.25	0
	BASDAI	1.0	1.9	-	-	-	-	-	1.6	4.2	-	-	0.1
	BASFI	1.0	0.5	-	-	-	-	-	0.0	1.1	-	-	0.0

Table S2 Demographics and MRI manifestations of patients with SAPHO syndrome

No.	Sex	Age	Disease duration (years)	Follow-up (months)	Lesions shown by MRI	Response to tofacitinib observed MRI	Figure in
1	F	41	4.5	3.3	Bilateral sternoclavicular joints and sternum; L4-5	Moderate	Fig S1a, S1b
2	F	53	7.6	4.1	Sternum; L1-2	Mild	Fig S2a, S2b
3	F	33	17.5	1.9	Right frontotemporal junction	Mild	Fig S3a, S3b
4	F	45	7.2	3.6	Right talus, calcaneus, navicular bone, cuboid, and tibia	Moderate	Fig S4a, S4b
5	F	38	2.3	3.2	Bilateral 1 <sup>st</sup> sternocostal joints	Moderate	Fig S5a, S5b
6	F	22	14.0	2.8	Left distal radius and carpal bones	Mild	Fig S6a, S6b
7	F	56	16.0	2.7	Bilateral mandible	None	Fig S7a, S7b
8	F	37	11.0	3.6	Left 1 <sup>st</sup> sternocostal joint; T6	None	Fig S8a, S8b
9	F	28	1.0	4.6	ACW; T5-6, L1	Moderate	Fig S9a, S9b
10	F	33	1.0	3.4	Bilateral 1 <sup>st</sup> sternocostal joints	Moderate	Fig S10a, S10b
11	F	54	1.0	2.8	Left clavicle and sternum	None	Fig S11a, S11b
12	F	33	0.3	3.5	T7-9	Moderate	Fig S12a, S12b

Fig S1a. Baseline




Fig S1b. After treatment




Fig S2a. Baseline




Fig S2b. After treatment




Fig S3a. Baseline




Fig S3b. After treatment




Fig S4a. Baseline




Fig S4b. After treatment




Fig S5a. Baseline




Fig S5b. After treatment




Fig S6a. Baseline



Fig S6b. After treatment





Fig S7a. Baseline




Fig S7b. After treatment




Fig S8a. Baseline



Fig S8b. After treatment




Fig S9a. Baseline




Fig S9b. After treatment




Fig S10a. Baseline




Fig S10b. After treatment




Fig S11a. Baseline




Fig S11b. After treatment




Fig S12a. Baseline



Fig S12b. After treatment

